Xarelto(rivaroxaban)
Rivaroxaban, Xarelto (rivaroxaban) is a small molecule pharmaceutical. Rivaroxaban was first approved as Xarelto on 2008-09-30. It is used to treat pulmonary embolism and venous thrombosis in the USA. It has been approved in Europe to treat acute coronary syndrome, atrial fibrillation, coronary artery disease, peripheral arterial disease, and pulmonary embolism amongst others. The pharmaceutical is active against coagulation factor X.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Rivaroxaban, Xarelto (discontinued: Rivaroxaban)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Rivaroxaban
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| XARELTO | Johnson & Johnson | N-022406 RX | 2011-07-01 | 4 products, RLD |
| XARELTO | Johnson & Johnson | N-215859 RX | 2021-12-20 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| rivaroxaban | ANDA | 2025-08-19 |
| rivaroxaban granule | ANDA | 2025-09-22 |
| xarelto | New Drug Application | 2025-08-27 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| venous thrombosis | — | D020246 | I82.40 |
| pulmonary embolism | EFO_0003827 | D011655 | I26 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
RIVAROXABAN, XARELTO, JANSSEN PHARMS | |||
| 2025-06-20 | PED | ||
| 2025-02-23 | PED | ||
| 2024-12-20 | NP | ||
| 2024-08-23 | I-867 | ||
| 2023-09-10 | PED | ||
| 2023-04-11 | PED | ||
| 2023-03-10 | M-284 | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Rivaroxaban, Xarelto, Janssen Pharms | |||
| 10828310 | 2039-01-31 | U-3207, U-3208 | |
| 9539218 | 2034-02-17 | U-1953, U-1954, U-1955, U-1957, U-2143, U-2641, U-3285, U-3288, U-3289 | |
| 9415053 | 2024-11-13 | DP | U-1167, U-1200, U-1301, U-1302, U-2142, U-2435, U-2640, U-3205, U-3206, U-3284, U-3286, U-3287 |
| 7157456 | 2024-08-28 | DS, DP | U-1301, U-1302 |
HCPCS
No data
Clinical
Clinical Trials
652 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | 2 | 4 | 8 | 3 | 44 | 60 |
| Venous thromboembolism | D054556 | EFO_0004286 | I74 | 1 | 6 | 14 | 1 | 21 | 43 |
| Thromboembolism | D013923 | — | — | 2 | 5 | 15 | 1 | 7 | 29 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | 1 | 7 | 1 | 18 | 27 |
| Thrombosis | D013927 | — | — | 4 | 2 | 6 | 1 | 9 | 22 |
| Venous thrombosis | D020246 | — | I82.40 | 4 | 3 | 3 | 1 | 11 | 22 |
| Pulmonary embolism | D011655 | EFO_0003827 | I26 | — | 1 | 3 | 4 | 10 | 18 |
| Embolism | D004617 | — | — | 3 | 1 | 1 | 2 | 10 | 17 |
| Peripheral arterial disease | D058729 | EFO_0004265 | — | — | — | 2 | 2 | 5 | 9 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | 2 | 2 | 1 | 3 | 8 |
Show 11 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acute coronary syndrome | D054058 | EFO_0005672 | — | — | 2 | 1 | — | 5 | 8 |
| Transient ischemic attack | D002546 | EFO_0003764 | G45.9 | — | 1 | 2 | — | 2 | 5 |
| Ischemic stroke | D000083242 | — | — | — | 1 | 1 | — | 2 | 4 |
| Heart failure | D006333 | EFO_0003144 | I50 | — | — | 2 | — | 1 | 3 |
| Syndrome | D013577 | — | — | — | 1 | 1 | — | — | 2 |
| Percutaneous coronary intervention | D062645 | — | — | — | — | 1 | — | 1 | 2 |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | — | 2 | — | — | 2 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | 1 | 1 | — | — | 2 |
| Cardiac arrhythmias | D001145 | EFO_0004269 | I49.9 | — | — | 2 | — | — | 2 |
| Hematoma | D006406 | EFO_0010680 | — | — | — | 1 | — | — | 1 |
Show 20 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Vascular diseases | D014652 | EFO_0004264 | I77 | — | 1 | — | — | 1 | 2 |
| Bariatric surgery | D050110 | — | — | 1 | 1 | — | — | — | 2 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 6 | — | — | — | 1 | 7 |
| Renal insufficiency | D051437 | — | N19 | 1 | — | — | — | 2 | 3 |
| Pharmacokinetics | D010599 | — | — | 2 | — | — | — | — | 2 |
| Biological availability | D001682 | — | — | 2 | — | — | — | — | 2 |
| Morbid obesity | D009767 | EFO_0001074 | — | 1 | — | — | — | — | 1 |
| Drug interactions | D004347 | — | — | 1 | — | — | — | — | 1 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 1 | — | — | — | — | 1 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | 1 | — | — | — | — | 1 |
| Hemophilia b | D002836 | — | D67 | 1 | — | — | — | — | 1 |
| Therapeutic equivalency | D013810 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Intracranial hemorrhages | D020300 | EFO_0000551 | I62 | — | — | — | — | 3 | 3 |
| Ischemia | D007511 | EFO_0000556 | — | — | — | — | — | 2 | 2 |
| Gastrointestinal hemorrhage | D006471 | — | K92.2 | — | — | — | — | 2 | 2 |
| Personal satisfaction | D010549 | — | — | — | — | — | — | 2 | 2 |
| Replacement arthroplasty knee | D019645 | — | — | — | — | — | — | 2 | 2 |
| Replacement arthroplasty hip | D019644 | — | — | — | — | — | — | 2 | 2 |
| Brain ischemia | D002545 | EFO_0003883 | I67.82 | — | — | — | — | 1 | 1 |
| Congenital heart defects | D006330 | — | Q24.9 | — | — | — | — | 1 | 1 |
| Fontan procedure | D018729 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Rivaroxaban |
| INN | rivaroxaban |
| Description | Rivaroxaban is a monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-chlorothiophene-2-carboxylic acid with the amino group of 4-{4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl}morpholin-3-one. It is an anticoagulant used for prophylaxis of venous thromboembolism in patients with knee or hip replacement surgery. It has a role as an anticoagulant and an EC 3.4.21.6 (coagulation factor Xa) inhibitor. It is a member of thiophenes, an organochlorine compound, an oxazolidinone, a member of morpholines, a lactam, an aromatic amide and a monocarboxylic acid amide. Rivaroxaban is an orally bioavailable oxazolidinone derivative and direct inhibitor of the coagulation factor Xa with anticoagulant activity. Upon oral administration, rivaroxaban selectively binds to both free factor Xa and factor Xa bound in the prothrombinase complex. This interferes with the conversion of prothrombin (factor II) to thrombin and eventually prevents the formation of cross-linked fibrin clots. Rivaroxaban does not affect existing thrombin levels. |
| Classification | Small molecule |
| Drug class | antithrombotics, blood coagulation factor XA inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1 |
Identifiers
| PDB | — |
| CAS-ID | 366789-02-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL198362 |
| ChEBI ID | 68579 |
| PubChem CID | 9875401 |
| DrugBank | DB06228 |
| UNII ID | 9NDF7JZ4M3 (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Xarelto – Johnson & Johnson
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Rivaroxaban
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 24,848 documents
View more details
Safety
Black-box Warning
Black-box warning for: Rivaroxaban, Rivaroxaban granule, Xarelto
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
147,117 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use